Evidence-based pharmacotherapy of obsessive-compulsive disorder
- PMID: 22226028
- DOI: 10.1017/S1461145711001829
Evidence-based pharmacotherapy of obsessive-compulsive disorder
Abstract
Pharmacological strategies for the treatment of obsessive-compulsive disorder (OCD) continue to develop apace but deficiencies remain. We present an updated literature review of the evidence supporting available strategies. We aim to answer key questions including: (1) What are the first-line treatments? (2) Does pharmacotherapy improve health-related quality of life? (3) How do we evaluate clinical response and relapse? (4) How long should treatment continue? (5) Can we predict treatment outcomes? (6) What is the management of treatment-refractory OCD? Selective serotonin reuptake inhibitors (SSRIs) remain the pharmacological treatment of choice for most patients and are associated with improved health-related quality of life. However, discontinuation is associated with relapse and loss of quality of life, implying treatment should continue long term. A substantial minority of patients fail to respond to SSRI. Such patients may respond to strategies such as dose elevation or adjunctive antipsychotic, although long-term trials validating the effectiveness and tolerability of these strategies are relatively lacking. Newer compounds targeting other neurotransmitter systems, such as glutamate, are undergoing evaluation.
Similar articles
-
Pharmacotherapy of obsessive-compulsive disorder: evidence-based treatment and beyond.Aust N Z J Psychiatry. 2013 Feb;47(2):121-41. doi: 10.1177/0004867412461958. Epub 2012 Nov 2. Aust N Z J Psychiatry. 2013. PMID: 23125399 Review.
-
Evidence-based pharmacotherapy of obsessive-compulsive disorder.Int J Neuropsychopharmacol. 2005 Mar;8(1):107-29. doi: 10.1017/S1461145704004675. Epub 2004 Sep 28. Int J Neuropsychopharmacol. 2005. PMID: 15450126 Review.
-
A Systematic Review of Evidence-based Treatment Strategies for Obsessive- compulsive Disorder Resistant to first-line Pharmacotherapy.Curr Med Chem. 2018;25(41):5647-5661. doi: 10.2174/0929867325666171222163645. Curr Med Chem. 2018. PMID: 29278206
-
Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis.J Clin Psychiatry. 2016 May;77(5):e605-11. doi: 10.4088/JCP.14r09758. J Clin Psychiatry. 2016. PMID: 27249090
-
Pharmacotherapy for obsessive-compulsive disorder.Br J Psychiatry Suppl. 1998;(35):64-70. Br J Psychiatry Suppl. 1998. PMID: 9829028 Review.
Cited by
-
Neurobiology of Obsessive-Compulsive Disorder from Genes to Circuits: Insights from Animal Models.Neurosci Bull. 2024 Dec;40(12):1975-1994. doi: 10.1007/s12264-024-01252-9. Epub 2024 Jul 9. Neurosci Bull. 2024. PMID: 38982026 Review.
-
Marble burying and nestlet shredding as tests of repetitive, compulsive-like behaviors in mice.J Vis Exp. 2013 Dec 24;(82):50978. doi: 10.3791/50978. J Vis Exp. 2013. PMID: 24429507 Free PMC article.
-
Ketamine induces immediate and delayed alterations of OCD-like behavior.Psychopharmacology (Berl). 2020 Mar;237(3):627-638. doi: 10.1007/s00213-019-05397-8. Epub 2020 Jan 11. Psychopharmacology (Berl). 2020. PMID: 31927606
-
Boosting Serotonin Increases Information Gathering by Reducing Subjective Cognitive Costs.J Neurosci. 2023 Aug 9;43(32):5848-5855. doi: 10.1523/JNEUROSCI.1416-22.2023. Epub 2023 Jul 31. J Neurosci. 2023. PMID: 37524494 Free PMC article.
-
Glutamatergic medications as adjunctive therapy for moderate to severe obsessive-compulsive disorder in adults: a systematic review and meta-analysis.BMC Pharmacol Toxicol. 2021 Nov 4;22(1):69. doi: 10.1186/s40360-021-00534-6. BMC Pharmacol Toxicol. 2021. PMID: 34736541 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
